The benefits of peptide therapy have become one of the most searched topics in functional medicine, and for good reason. Peptides are short chains of amino acids that act as signaling molecules in your body, telling specific systems to do specific things: release growth hormone, accelerate tissue repair, modulate immune response, improve sexual function. Your body already produces hundreds of them. Therapeutic peptides work by supplementing or mimicking those natural signals when your own production has declined or when a targeted clinical effect is needed.
But the conversation around peptide therapy has gotten noisy. Social media influencers promote peptides as miracle anti-aging compounds. Online vendors sell unregulated products with no clinical oversight. And the FDA has been actively reclassifying which peptides can and cannot be legally compounded, creating confusion for patients and providers alike.
This guide cuts through that noise. We will cover what peptide therapy actually is, which peptides have real clinical evidence behind them, what the FDA’s current regulatory position means for patients, and how iRevive Integrative & Functional Medicine approaches peptide protocols with the kind of clinical rigor this category demands.
What Is Peptide Therapy and How Does It Work?
Peptide therapy involves the clinical use of specific amino acid sequences to trigger targeted biological responses. Unlike pharmaceuticals that often block a pathway or suppress a symptom, peptides generally work by enhancing or restoring a function your body already performs. They are signaling molecules, not blunt instruments.
The human body produces over 7,000 known peptides that regulate everything from growth hormone secretion and immune function to inflammation and tissue repair. As you age, production of many of these peptides declines. Growth hormone output, for example, drops approximately 14% per decade after age 30, according to research published in the Journals of Gerontology. That decline contributes to reduced lean muscle mass, increased visceral fat, slower recovery, and diminished sleep quality.
Therapeutic peptides are administered via subcutaneous injection, topical application, nasal spray, or IV infusion, depending on the specific peptide and its target. They are prescribed by licensed providers and, when sourced properly, prepared by regulated compounding pharmacies using USA-sourced ingredients. That sourcing detail matters more than most patients realize, and we will return to it.
What Are the Documented Benefits of Peptide Therapy?
The benefits of peptide therapy vary by the specific peptide used. This is not a single treatment with a single outcome. It is a category of treatments, each with distinct mechanisms and distinct levels of evidence. Lumping them all together is one of the biggest mistakes in how peptides are discussed online.
Growth Hormone Optimization
Growth hormone secretagogues like sermorelin stimulate your pituitary gland to produce and release more of your own growth hormone. This is fundamentally different from injecting synthetic growth hormone directly. Your body’s feedback loops remain intact, which means the release pattern stays physiological rather than creating unnaturally sustained spikes.
Sermorelin, a GHRH analogue that was FDA-approved in 1997 for growth hormone deficiency in children, has demonstrated consistent results in adult populations. Studies show increases in IGF-1 levels of 20% to 40% over treatment cycles of three to six months, with improvements in body composition (reduced body fat, increased lean mass), sleep architecture, skin thickness, and recovery time. A 2009 review in Clinical Interventions in Aging concluded that sermorelin offers a more physiologically appropriate approach to managing age-related growth hormone insufficiency than direct GH injection.
Tesamorelin is an FDA-approved GHRH analogue — the only growth hormone secretagogue in this category with full FDA approval, marketed as Egrifta for HIV-associated lipodystrophy. It has demonstrated statistically significant reductions in visceral adiposity in Phase 3 randomized controlled trials, with IGF-1 improvements comparable to sermorelin. In functional medicine practice, tesamorelin is used in patients where visceral fat reduction is a primary clinical goal, particularly when combined with broader hormone optimization protocols. Because it carries FDA approval, its evidence base is the strongest in this category.
CJC-1295, a long-acting GHRH analogue, is often used in combination with ipamorelin. The mechanistic data is sound, and early clinical observations are promising. But it is important to be honest about where the evidence stands: large-scale, randomized controlled trials examining its effects on muscle mass, body fat, and sleep quality in humans have not been completed. The research is encouraging. It is not yet definitive. That distinction matters when you are making decisions about your own health.
Ipamorelin is a selective growth hormone releasing peptide (GHRP) and ghrelin mimetic that works through a different receptor pathway than GHRH analogues like sermorelin and CJC-1295. Rather than stimulating GHRH release, ipamorelin directly activates ghrelin receptors in the pituitary, producing a clean, pulsatile release of growth hormone with minimal effect on cortisol or prolactin — a selectivity profile that distinguishes it from earlier GHRPs like GHRP-2 and GHRP-6. When combined with CJC-1295, the two peptides work synergistically: CJC-1295 amplifies the GH pulse, while ipamorelin refines its timing and selectivity. Early clinical observations support improvements in sleep quality, body composition, and recovery, though large-scale human RCTs remain incomplete.
Tissue Repair and Recovery
BPC-157 (Body Protection Compound-157) is probably the most talked-about peptide in the recovery space. Derived from a protein found in gastric juice, BPC-157 has shown remarkable regenerative effects in animal studies, including accelerated healing of tendons, ligaments, muscles, nerves, and intestinal lining. It promotes fibroblast activity, modulates nitric oxide pathways, and enhances angiogenesis (the formation of new blood vessels to injured tissue).
The clinical reality is more nuanced. As of 2026, there are no large, published human randomized controlled trials for BPC-157. A small 2025 pilot study reported short-term tolerability, but the robust human efficacy data that clinicians want to see simply does not exist yet. The animal data is extensive and consistently positive, which is why many functional medicine practitioners consider it a promising therapeutic tool, but patients should understand the current evidence level when making informed decisions.
TB-500 (Thymosin Beta-4) is a naturally occurring peptide present in virtually all human and animal cells, where it plays a central role in the regulation of actin — a protein essential to cell structure, migration, and repair. In preclinical studies, TB-500 has demonstrated meaningful acceleration of wound healing, muscle repair, and tendon and ligament recovery, as well as anti-inflammatory effects and promotion of new blood vessel formation in injured tissue. Its mechanism is complementary to but distinct from BPC-157: where BPC-157 primarily modulates growth factor signaling and nitric oxide pathways, TB-500 acts on the cytoskeletal and cellular migration machinery that governs how repair cells actually reach and rebuild damaged tissue. As of 2026, TB-500 is classified as a Category 2 substance by the FDA, making it ineligible for routine compounding through 503A pharmacies. Human clinical trial data remains limited, and patients should approach it with the same evidence-level transparency applied to BPC-157.
GHK-Cu, a copper peptide that occurs naturally in human serum, supports wound healing, collagen synthesis, and skin regeneration. Serum levels of GHK-Cu decline from approximately 200 ng/mL at age 20 to 80 ng/mL by age 60. Topical applications have the strongest evidence base, with documented improvements in skin elasticity, firmness, and wound healing rates. It remains available for compounding as a Category 1 substance.
Immune Support
Thymosin alpha-1 modulates immune function by enhancing T-cell maturation and activity. It has demonstrated clinical efficacy in the treatment of hepatitis B and C and has been used as an adjunctive therapy in certain cancers in countries where it holds regulatory approval. In the United States, it has FDA orphan drug designation but is not FDA-approved for general use. Its compounding status is currently Category 2, which limits availability.
Sexual Health
PT-141 (bremelanotide) is one of the few peptides with full FDA approval, marketed as Vyleesi for hypoactive sexual desire disorder in premenopausal women. Unlike PDE5 inhibitors that work on blood flow mechanics, PT-141 acts on melanocortin receptors in the central nervous system, promoting a natural arousal response at the neurological level. Phase 3 clinical trials demonstrated statistically significant improvements in desire and reduction in distress related to low sexual desire.
Cellular Energy and Longevity
NAD+ (nicotinamide adenine dinucleotide) is technically a coenzyme rather than a peptide, but it is commonly grouped with peptide therapies in clinical practice. NAD+ is central to mitochondrial energy production, DNA repair, and cellular signaling. Levels decline with age, and declining NAD+ is associated with reduced energy metabolism, impaired cognitive function, and accelerated cellular aging. IV NAD+ infusions and NAD+ precursors (NMN, NR) are used to restore intracellular levels, with a growing body of human research supporting benefits in metabolic function and cognitive performance.
Peptide Therapy Types: A Clinical Comparison
The following table compares the most commonly used peptides in functional medicine, including their FDA status, evidence level, and current compounding availability.
| Peptide | Category | Primary Applications | FDA Status | Evidence Level | Available for Compounding (2026) |
| Sermorelin | Growth hormone secretagogue (GHRH analogue) | Age-related GH decline, body composition, sleep quality, recovery | Previously FDA-approved (1997); discontinued commercially 2008 | Strong: human clinical trials in children and adults | Yes (Category 1) |
| Tesamorelin | Growth hormone secretagogue (GHRH analogue) | Visceral adiposity, body composition, GH deficiency (HIV-associated lipodystrophy) | FDA-approved (Egrifta, 2010) for HIV-associated lipodystrophy | Strong: Phase 3 RCTs; FDA-approved indication | Yes — available as FDA-approved product (Egrifta) |
| CJC-1295 | Growth hormone secretagogue (GHRH analogue) | GH optimization, lean mass, fat reduction, sleep, recovery | Not FDA-approved | Moderate: mechanistic and early clinical data; no large RCTs in humans | Regulatory status in flux (Category 2; potential reclassification pending) |
| Ipamorelin | Growth hormone secretagogue (GHRP / ghrelin mimetic) | GH pulse stimulation, sleep quality, body composition, appetite modulation | Not FDA-approved | Moderate: animal studies and early human observations; no large RCTs | Regulatory status in flux (Category 2; potential reclassification pending) |
| BPC-157 | Regenerative / healing | Tissue repair, gut healing, tendon/ligament recovery, inflammation | Not FDA-approved | Preclinical: extensive animal data; limited human trials | Category 2 (not currently available for 503A compounding) |
| TB-500 (Thymosin Beta-4) | Regenerative / healing | Muscle repair, tendon/ligament recovery, wound healing, inflammation reduction | Not FDA-approved | Preclinical: animal studies showing accelerated tissue repair; limited human data | Category 2 (not currently available for 503A compounding) |
| PT-141 (Bremelanotide) | Sexual health | Hypoactive sexual desire disorder in women | FDA-approved (Vyleesi, 2019) | Strong: Phase 3 clinical trials | Yes (active ingredient in FDA-approved drug) |
| GHK-Cu | Regenerative / skin health | Wound healing, collagen synthesis, skin rejuvenation, hair growth | Not FDA-approved as a drug; used in cosmetic applications | Moderate: human studies for topical applications; limited systemic data | Yes, topical (Category 1) |
| NAD+ | Cellular energy / longevity | Cellular repair, mitochondrial function, energy metabolism, cognitive support | Not FDA-approved as a drug; classified as supplement in oral form | Moderate: growing human data on NAD precursors (NMN, NR); IV NAD+ less studied | Yes (available for IV and other compounded formulations) |
| Thymosin Alpha-1 | Immune modulation | Immune support, chronic infections, autoimmune conditions, post-illness recovery | FDA-approved in some countries (not US); FDA orphan drug designation | Moderate to strong: clinical use in hepatitis B/C, cancer adjunct | Category 2 (not currently available for 503A compounding) |
What Is the FDA’s Current Position on Peptide Therapy?
This is where peptide therapy gets complicated, and it is also where patients need the most clarity.
In late 2023, the FDA reclassified 19 peptides from Category 1 (eligible for routine compounding) to Category 2 (significant safety concerns identified; not eligible for standard compounding). This included several widely used peptides: BPC-157, TB-500, GHRP-2, GHRP-6, and others. The FDA cited unresolved safety questions, including potential cancer-promoting effects from growth hormone-related peptides and insufficient human safety data for regenerative peptides.
As of April 2026, several peptides remain available for legal compounding through 503A pharmacies: sermorelin, gonadorelin, GHK-Cu (topical), and NAD+. PT-141 is available as the FDA-approved product Vyleesi. Tesamorelin is available as the FDA-approved product Egrifta. The regulatory picture for CJC-1295 and ipamorelin remains in flux, with HHS Secretary Kennedy publicly discussing potential reclassification of up to 14 Category 2 peptides back to Category 1. No formal regulatory action has been taken on that front as of this writing.
What does this mean for patients? It means sourcing matters enormously. Peptides obtained from unregulated online vendors, overseas pharmacies, or “research chemical” suppliers carry real risks: contamination, incorrect concentrations, degraded compounds, and no clinical oversight. Working with a provider who sources exclusively from regulated, USA-based compounding pharmacies is not a marketing talking point. It is a safety requirement.
How iRevive Uses Peptide Therapy in Clinical Practice
At our clinic in Bradenton, serving patients across Florida, Sarasota, Lakewood Ranch, and Venice, Florida, peptide therapy is one tool within a larger functional medicine framework. We do not prescribe peptides in isolation, and we do not prescribe them to everyone.
Every peptide protocol starts with comprehensive biomarker analysis. We evaluate IGF-1 levels, inflammatory markers, metabolic indicators, and hormonal status before determining whether a specific peptide is appropriate for your clinical picture. If your growth hormone markers are already in an optimal range, a secretagogue is not the right starting point. If your symptoms point to a thyroid or sex hormone issue, that is where we begin, not with a peptide that does not address the root cause.
When peptides are indicated, we source exclusively from USA-based compounding pharmacies and monitor your response through follow-up lab work and clinical assessment. Our concierge model means you have direct access to Ryan Hentges, FMNP-C, throughout the process. Protocol adjustments happen in real time, not at your next appointment three months from now.
Peptide therapy works best when it is part of a coordinated strategy alongside hormone optimization, nutritional support, exercise programming, and lifestyle modification. The patients who get the most out of peptides are the ones whose providers are managing the full picture, not just writing a prescription for the latest trending compound.
Who Is a Good Candidate for Peptide Therapy?
Peptide therapy may be appropriate for adults experiencing age-related decline in growth hormone production, slow recovery from injury or surgery, persistent fatigue or poor sleep quality despite lifestyle optimization, body composition changes that have not responded to diet and exercise, or specific conditions like low sexual desire (where PT-141 has FDA approval).
It is not appropriate for everyone. Patients with active cancer or a history of certain cancers may not be candidates for growth hormone secretagogues, as elevated IGF-1 levels carry theoretical oncological risk. Pregnant or breastfeeding women should not use peptide therapy. And anyone with unrealistic expectations, looking for a shortcut rather than a component of a comprehensive health strategy, is likely to be disappointed.
The best outcomes come from patients who approach peptide therapy as an informed decision, understand the evidence level for their specific peptide, and work with a provider who monitors their response objectively through lab work rather than relying solely on subjective reports.
Frequently Asked Questions
What are the main benefits of peptide therapy?
The benefits of peptide therapy depend on the specific peptide used. Growth hormone secretagogues like sermorelin and tesamorelin can improve body composition, sleep quality, and recovery. Ipamorelin stimulates clean, pulsatile GH release with a favorable selectivity profile. BPC-157 shows promise for tissue repair and gut healing based on preclinical data. TB-500 supports muscle and connective tissue repair through complementary cellular mechanisms. PT-141 is FDA-approved for low sexual desire. NAD+ supports cellular energy and cognitive function. Each peptide targets a different biological system, so the benefits are specific to the compound and your individual clinical needs.
Is peptide therapy FDA-approved?
Some peptides have FDA approval for specific indications. PT-141 (bremelanotide/Vyleesi) is approved for hypoactive sexual desire disorder. Tesamorelin (Egrifta) is FDA-approved for HIV-associated lipodystrophy. Semaglutide and tirzepatide are FDA-approved peptides for diabetes and weight management. Others, like sermorelin, were previously FDA-approved but are now available only through compounding pharmacies. Many peptides used in functional medicine have not completed the FDA approval process, which means they are prescribed based on clinical judgment and available evidence.
Are peptides safe?
Peptides prescribed by a licensed provider and sourced from regulated compounding pharmacies have generally favorable safety profiles. Sermorelin, for example, has decades of clinical use with minimal adverse effects. However, safety depends on the specific peptide, your health history, proper dosing, and ongoing monitoring. Growth hormone secretagogues carry theoretical oncological risks in patients with certain cancer histories. Unregulated peptides from online vendors carry additional risks including contamination and incorrect dosing.
How long does it take to see results from peptide therapy?
Timeline varies by peptide and individual response. Many patients report improvements in sleep quality within the first two to four weeks of growth hormone secretagogue therapy. Body composition changes typically become measurable at eight to twelve weeks. Full treatment cycles for sermorelin and similar peptides run three to six months, with IGF-1 levels monitored via lab work to objectively track response.
How much does peptide therapy cost?
Peptide therapy costs vary based on the specific peptide, delivery method, and provider model. Individual peptide medications typically range from $100 to $400 per month. Comprehensive protocols that include provider consultations, lab work, and ongoing monitoring can range from $200 to $600 monthly. At iRevive, our $99/month concierge membership covers clinical oversight, with peptide medication costs separate based on your personalized protocol.
Can peptide therapy be combined with hormone therapy?
Yes, and in many cases this combination produces the best clinical outcomes. Peptide therapy and hormone optimization address different but complementary biological systems. A patient optimizing testosterone through bioidentical hormone therapy may also benefit from a growth hormone secretagogue to address age-related GH decline. The key is coordinated management under a single provider who can monitor interactions and adjust both protocols based on your lab results.
Which peptides are currently legal and available?
As of April 2026, peptides available for legal compounding through 503A pharmacies include sermorelin, gonadorelin, GHK-Cu (topical), and NAD+. PT-141 is available as the FDA-approved product Vyleesi. Tesamorelin is available as the FDA-approved product Egrifta. Several previously available peptides, including BPC-157 and TB-500, are currently classified as Category 2 by the FDA, making them ineligible for routine compounding. Regulatory discussions about potential reclassification are ongoing but no formal changes have been implemented.
Medical Disclaimer
This article is for educational purposes only and is not intended as medical advice. Peptide therapy should only be initiated under the supervision of a licensed healthcare provider. Individual results vary based on health status, specific peptides used, and treatment protocols. Always consult with a qualified provider before beginning any peptide therapy. FDA regulatory classifications referenced in this article are current as of April 2026 and are subject to change.
